RECURSION PHARMACEUTICALS, INC. (RXRX)
RECURSION PHARMACEUTICALS, INC. (RXRX)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | NaN | 35,538 | 5,175 | NaN |
| Salaries | NaN | 68,288 | 68,599 | NaN |
| Consumables | NaN | 10,180 | 8,927 | NaN |
| Platform | NaN | 12,275 | 14,377 | NaN |
| Discovery | NaN | 9,477 | 37,049 | NaN |
| Clinical development | NaN | 13,045 | 10,814 | NaN |
| Depreciation and amortization | NaN | 19,478 | 18,707 | NaN |
| Other segment items | NaN | 11,129 | 18,905 | NaN |
| Loss from operations | NaN | -108,334 | -172,203 | NaN |
| Other non-operating income, net | NaN | 232 | 9,952 | NaN |
| Income tax benefit | NaN | 20 | 2 | NaN |
| Net loss | -117,504 | -108,122 | -162,253 | -171,897 |
| Depreciation and amortization | 19,673 | 19,478 | 21,043 | 23,849 |
| Stock-based compensation | 22,215 | 23,763 | 25,243 | 26,159 |
| Asset impairment | 0 | 0 | 0 | 0 |
| Lease expense | 5,243 | 5,230 | 5,264 | 5,625 |
| Loss on disposal of a business | 0 | 0 | 0 | 0 |
| Acquired ipr&d | NaN | 0 | 22,082 | NaN |
| Deferred income taxes | -4,597 | NaN | NaN | NaN |
| Other, net | -1,674 | -2,895 | 2,443 | -4,693 |
| Other receivables and assets | -14,746 | 836 | -3,529 | -25,407 |
| Prepaid data assets | 0 | -20,258 | 0 | -29,601 |
| Accrued data liability | NaN | NaN | 0 | 20,258 |
| Unearned revenue | -2,248 | -6,757 | -6,631 | -13,621 |
| Accounts payable | 2,070 | 4,419 | -5,890 | -4,837 |
| Accrued development expense | 730 | 1,882 | -4,055 | -754 |
| Accrued expenses and other current liabilities | -18,451 | 15,839 | -8,033 | 11,378 |
| Lease liabilities | -4,652 | -3,864 | -5,216 | -5,148 |
| Net cash used in operating activities | -81,101 | -46,073 | -117,360 | -76,418 |
| Net cash acquired in the acquisition of a business | NaN | 0 | NaN | NaN |
| Purchases of property and equipment | 258 | 1,244 | 243 | 3,150 |
| Purchase of an intangible asset | 80 | 0 | 0 | 2,158 |
| Decrease in cash related to disposal of a business | 0 | 0 | 0 | 0 |
| Purchases of investments | 0 | 0 | 2,306 | 500 |
| Sales and maturities of investments | NaN | 0 | NaN | NaN |
| Net cash used in investing activities | -338 | -1,244 | -2,549 | -5,808 |
| Proceeds from issuance of common shares, net of issuance costs | 0 | 133,380 | 254,460 | 100,000 |
| Proceeds from equity incentive plans | NaN | 793 | -993 | 2,743 |
| Equity incentive plans | -1,262 | NaN | NaN | NaN |
| Repayment of long-term debt and finance lease liabilities | 2,208 | 2,167 | 2,127 | 2,084 |
| Purchase of an intangible asset | NaN | 0 | 0 | 3,000 |
| Net cash provided by (used in) financing activities | -3,470 | 132,006 | 251,340 | 97,659 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -3,832 | 2,087 | 1,869 | 9,255 |
| Net change in cash, cash equivalents and restricted cash | -88,741 | 86,776 | 133,300 | 24,688 |
| Cash, cash equivalents and restricted cash, beginning of period | 753,921 | 667,145 | 533,845 | 509,157 |
| Cash, cash equivalents and restricted cash, end of period | 665,180 | 753,921 | 667,145 | 533,845 |